Document Detail

Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.
MedLine Citation:
PMID:  9543168     Owner:  NLM     Status:  MEDLINE    
Little is known about differences in the expression, localization, and function of the two dopamine D2 receptor subtypes, D2short and D2long (D2s and D2l), in either normal or adenomatous pituitary. We investigated the messenger RNA (mRNA) expression of the D2 receptor (D2R) subtypes in clinically nonfunctioning pituitary adenomas by in situ hybridization using subtype-specific oligonucleotides. The five normal pituitaries studied expressed similar ratios of D2R subtypes mRNA with a predominant expression of the D2l isoform. In 2 of 18 clinically inactive adenomas no D2R mRNA was found, whereas in 16 a heterogeneous expression of D2R isoforms was observed. Six adenomas expressed only the D2l and 2 adenomas only the D2s subtype mRNA; the remaining 8 expressed extremely varying proportions of the two subtypes. The D2R was found only in a subset of the nonfunctioning adenoma cells. In gonadotropin-immunopositive adenomas, the D2R was mainly localized in LH- and FSH-immunopositive cells. Probably because of the heterogeneous D2R subtype expression, suppression of cell proliferation was observed in only 3 of 9 adenoma cell cultures in which the growth inhibitory effect of bromocriptine was studied. Although there is some evidence that the presence of the D2s receptor subtype favors the growth inhibitory response to bromocriptine, further studies with a larger number of inactive adenomas are needed to confirm this speculation.
U Renner; T Arzberger; U Pagotto; S Leimgruber; E Uhl; A Müller; M Lange; A Weindl; G K Stalla
Related Documents :
20175188 - Expression patterns of hormones, signaling molecules, and transcription factors during ...
23515868 - Effects of low-level laser therapy on the expression of osteogenic genes related in the...
18285528 - Effects of a high-glucose environment on the pituitary growth hormone-releasing hormone...
20651098 - Cyclic morphological changes in the beagle mammary gland.
17089188 - Increased activity and expression of gelatinases in ischemic colitis.
23429718 - Reprogramming human fibroblasts to pluripotency using modified mrna.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  83     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1998 Apr 
Date Detail:
Created Date:  1998-04-21     Completed Date:  1998-04-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1368-75     Citation Subset:  AIM; IM    
Max-Planck-Institute of Psychiatry, Clinical Institute, Department of Endocrinology, Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoma / metabolism*,  pathology
Aged, 80 and over
Bromocriptine / therapeutic use
Case-Control Studies
Dopamine Agonists / therapeutic use
In Situ Hybridization
Middle Aged
Pituitary Gland / cytology,  metabolism*
Pituitary Neoplasms / metabolism*,  pathology
RNA, Messenger / biosynthesis*
Receptors, Dopamine D2 / genetics*
Tumor Cells, Cultured
Reg. No./Substance:
0/Dopamine Agonists; 0/RNA, Messenger; 0/Receptors, Dopamine D2; 25614-03-3/Bromocriptine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prostaglandin endoperoxide H synthase (PGHS) activity and PGHS-1 and -2 messenger ribonucleic acid a...
Next Document:  The human placenta and fetal membranes express the corticotropin-releasing hormone receptor 1alpha (...